Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MELO: Low Dose Psilocybin in Healthy Subjects
NCT05252598Phase 1Withdrawn
- Sponsor
- Optimi Health
- Start
- Jan 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of Melocin in mood disorder, anxiety disorder, sleep disorder and 1 more (6 arms), sponsored by Optimi Health. Primary endpoints: Incidence of Adverse Events and Altered States of Consciousness Scale. Planned start Jan 2023; status: withdrawn.
02
Drugs
Melocin
03
Conditions
mood disorderanxiety disordersleep disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05252598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05252598.